The Medicines Company will present results of recent clinical studies from its cardiovascular product portfolio at the 2015 European Society of Cardiology (ESC) Congress (29 August–2 September, London, UK).
The presentations at ESC 2015 will include a poster presentation of the Phase 1 results for ALN-PCSsc, a subcutaneously administered investigational RNAi therapeutic targeting PCSK9 being developed for the treatment of hypercholesterolemia. Alnylam Pharmaceuticals conducted this trial under a collaboration agreement with The Medicines Company and will present the results on Sunday 30 August.
Several posters and presentations focusing on The Medicines Company’s novel intravenous antiplatelet agent, Kengreal/Kengrexal (cangrelor) as well as the company’s direct thrombin inhibitor, Angiomax/Angiox (bivalirudin), will also be presented during the meeting, including a presentation on Monday 31 August titled “The effect of cangrelor and access site on ischemic and bleeding events: insights from CHAMPION-PHOENIX”.
